CEMQ:F:F-iShares Edge MSCIope Quality Factor UCITS (EUR)

ETF | Others |

Last Closing

USD 10.282

Change

+0.10 (+0.98)%

Market Cap

USD 0.46B

Volume

N/A

Analyst Target

N/A
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2025-04-24 )

Largest Industry Peers for Others

Symbol Name Price(Change) Market Cap
SXR8:F iShares Core S&P 500 UCITS ETF..

+13.16 (+2.61%)

USD 101.74B
UIM5:F UBS (Lux) Fund Solutions - MSC..

+0.38 (+0.76%)

USD 101.37B
ZPDJ:F SPDR® MSCI Japan UCITS ETF

+0.37 (+0.68%)

USD 96.03B
XDNY:F Xtrackers MSCI Japan ESG Scree..

+0.14 (+0.98%)

USD 57.02B
XJSE:F Xtrackers II - Japan Governmen..

-0.07 (-0.95%)

USD 53.72B
VUSA:F Vanguard Funds Public Limited ..

+0.89 (+0.97%)

USD 51.63B
SXRZ:F iShares VII PLC - iShares Nikk..

+1.10 (+0.50%)

USD 45.80B
0ZC:F Zscaler Inc

+12.08 (+6.91%)

USD 37.92B
BSND:F Danone SA

+0.40 (+2.78%)

USD 33.83B
VGWL:F Vanguard FTSE All-World UCITS ..

+0.46 (+0.39%)

USD 24.77B

ETFs Containing CEMQ:F

N/A

Market Performance

  Market Performance vs. Industry/Classification (Others) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 1.74% 75% C 69% C-
Dividend Return N/A N/A N/A N/A N/A
Total Return 1.74% 75% C 68% D+
Trailing 12 Months  
Capital Gain 2.72% 54% F 60% D-
Dividend Return N/A N/A N/A N/A N/A
Total Return 2.72% 52% F 52% F
Trailing 5 Years  
Capital Gain 62.87% 64% D 64% D
Dividend Return N/A N/A N/A N/A N/A
Total Return 62.87% 64% D 47% F
Average Annual (5 Year Horizon)  
Capital Gain 10.34% 70% C- 66% D+
Dividend Return 10.34% 68% D+ 58% F
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 12.45% 54% F 86% B+
Risk Adjusted Return 83.05% 81% B- 86% B+
Market Capitalization 0.46B 59% D- 47% F

Annual Financials (EUR)

Quarterly Financials (EUR)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior risk adjusted returns

This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.

What to not like:

There is nothing we particularly dislike